HMC Partners with AbbVie to Launch Clinical Research Training Program in Qatar
Key Insights
Hamad Medical Corporation has signed a memorandum of understanding with AbbVie Biopharmaceuticals Gulf Levant (search) to implement the Clinical Research Advancement Integrated Signature Programme (CRISP) at HMC.
The program provides clinical research professionals with world-class training, internationally recognized certification through ACRP, and ongoing professional support in areas including good clinical practice and patient safety.
CRISP has demonstrated regional success with over 700 certificates awarded to participants from more than 15 countries and has received accreditation from major health authorities.
Hamad Medical Corporation (HMC) has signed a memorandum of understanding with AbbVie Biopharmaceuticals Gulf Levant (search) to bring the Clinical Research Advancement Integrated Signature Programme (CRISP) to Qatar's leading healthcare institution. The partnership represents a significant investment in clinical research capacity building and aims to elevate the quality of medical research conducted in the region.
Comprehensive Training Initiative
The CRISP program is designed to provide clinical research professionals with access to world-class training, internationally recognized certification, and ongoing professional support. AbbVie, working in partnership with the Association of Clinical Research Professionals (search) (ACRP), the only non-profit organization dedicated exclusively to supporting clinical research professionals globally, will deliver a structured learning program for HMC's researchers and healthcare staff.
Through this collaboration, participants will benefit from a structured learning pathway and have the opportunity to earn ACRP certifications. The training curriculum will cover critical areas including good clinical practice, patient safety, research ethics, protocol design, inspection readiness, and the implementation of new research models.
Strategic Impact on Healthcare Quality
By adopting CRISP, HMC aims to further strengthen the quality and impact of its clinical research, ultimately supporting the development of safer, more effective treatments and better outcomes for patients. The partnership with AbbVie marks an important step to advance clinical research capabilities at HMC, with the goal of building stronger research capacity and ensuring that research work meets the highest global standards.
AbbVie Biopharmaceuticals Gulf Levant (search) emphasized the transformative nature of this partnership with Hamad Medical Corporation, highlighting the shared commitment of both organizations to excellence in clinical research across HMC and Qatar. The company noted that CRISP will help set new benchmarks in education, certification, and patient safety, empowering clinical research professionals to advance healthcare outcomes and raise the standards of care at HMC and beyond.
Proven Regional Success
Since its launch, CRISP has demonstrated significant growth and impact across the region. The program has awarded more than 700 certificates to participants from over 15 countries, indicating its broad acceptance and effectiveness in advancing clinical research capabilities. The program has also received accreditation from major health authorities, underlining its value as a proven model for advancing healthcare research and education.
The partnership ultimately seeks to benefit patients while helping position Qatar as a leader in medical innovation, contributing to the country's broader healthcare transformation goals and research excellence initiatives.